CDMO European Landscape in 2024

Exclusive new infographic summarises the main CDMO players operating facilities in Europe. 

The global market for biopharma Contract Development & Manufacturing (CDMO) is forecast to keep expanding. The European CDMO market is projected to grow at a CAGR of 5% to 6.5% according to various reports.

The rising demand for CDMO services presents both opportunities and challenges for Pharma companies and CDMOs alike.

Released ahead of CDMO Live 2024, this infographic summarises the main players with facilities in Europe who develop and manufacture Finished Dosage Forms (FDF) of small molecules, APIs and Biologics.

You can download a free high resolution infographic and request the full data table that this is based on by filling out the short form.

Methodology explained

This listing is based on analysis by Fuliginous Management Consulting. CDMOs included in the infographic have to meet the following criteria:

• Small Molecule Finished Dosage Form CDMOs: The list includes 41 CDMOs of Small Molecule FDF with least 1 site in Europe and operate 4 or more FDF sites internationally.

• API CDMOs: The list represents 45 CDMOs that offer API contract manufacturing services with at least 1 manufacturing site in Europe. Note: CDMOs that offer contract manufacturing services for both APIs and FDFs are not included in this list.

• Biologics CDMOs: The list contains 55 Bio CDMOs at least one manufacturing site in Europe.

Please get in touch with any comments or questions about the methodology.